Clinician-scientists at the institute participate in national and international clinical trials coordinated through hospitals in Victoria and throughout Australia.
How do I enrol in a clinical trial?
A number of treatments based on fundamental research and discoveries made at the institute are currently being trialled in patients.
The Walter and Eliza Hall Institute does not currently run clinical trials.
To join a clinical trial, the following sites will be useful:
To register a clinical trial or to find out information about clinical trials underway in Australia, visit Australian New Zealand Clinical Trials Registry.
We also recommend talking to your physician about new and upcoming clinical trials that might be suitable for you to participate in based on your condition.
Institute research in clinical trials
New anti-cancer agents that target 'immortal' cells
A scientific discovery made at the Walter and Eliza Hall Institute in 1988 led to the development of a new class of anti-cancer agents called BH3-mimetics, which are now in clinical trials worldwide.
BH3-mimetics are designed to block the function of the protein Bcl-2, which is over-expressed in a number of cancers, including some leukaemias, breast cancers and lung cancers. Navitoclax (ABT-263), a BH3-mimetic, is currently in:
- phase II clinical trials for chronic lymphocytic leukaemia (CLL) in Melbourne
- phase I and II clinical trials for CLL and other malignancies, including solid tumours such as lung cancer, worldwide
The institute’s medicinal chemists have also, through an in-house drug discovery program and in collaboration with healthcare companies Abbott and Genentech, a member of the Roche group, identified a clinical candidate compound, ABT-199, which commenced phase I clinical trials in 2011 for CLL in Melbourne and in the US.
A vaccine to treat coeliac disease
Dr Bob Anderson, Dr Jason Tye-Din and colleagues from the institute identified the three components of gluten that are toxic for people with coeliac disease, and were instrumental in the design of a vaccine to target these proteins.
The vaccine is being developed by ImmusanT, a biotechnology company based in the US. Dr Bob Anderson is now Chief Scientific and Medical Office for ImmusanT, which will be coordinating phase II clinical trials of the vaccine and will be releasing all information on clinical trial recruitment and progress.
When the trial is recruiting in Australia, it will be advertised on the Australian New Zealand Clinical Trials Registry.
A vaccine to prevent type 1 diabetes
Professor Len Harrison and colleagues from the institute have helped to develop an intranasal vaccine that aims to prevent the development of type 1 diabetes in high-risk individuals.
The vaccine is still in clinical trials. More information about the trial can be found at www.stopdiabetes.com.au. People who are interested in participating in the trial can register their interest online or contact Diabetes Australia Victoria on 1300 138 712.